All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021
Details:
Abu Dhabi has started Phase III clinical trials of Russia’s Sputnik V COVID-19 vaccine amid a surge in infections in the United Arab Emirates. Two doses of the vaccine will be given, 20 days apart, to volunteers.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 30, 2020
Details:
The Sputnik vaccine is being developed by Moscow's Gamaleya Research Institute and marketed by the Russian Direct Investment Fund (RDIF). Brazilian partner Uniao Quimica, a pharmaceutical company, entered the request with Anvisa.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: The Gamaleya National Center of Epidemiology and Microbiology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2020
Details:
Registering the Sputnik V vaccine based on the data from clinical trials in Russia confirms ANMAT’s high confidence in Russian regulatory standards.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: The Gamaleya National Center of Epidemiology and Microbiology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2020
Details:
The Russian Direct Investment Fund (RDIF) has confirmed efficacy of over 90% for the Sputnik V vaccine. The Sputnik V vaccine efficacy against severe cases of coronavirus was 100%.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2020
Details:
The efficacy of the Sputnik V vaccine is 91.4%, based on the second interim analysis of data obtained 28 days after administering the first dose (7 days after the second dose).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2020
Details:
The Sputnik V vaccine efficacy amounted to 92% (calculation based on the 20 confirmed COVID-19 cases split between vaccinated individuals and those who received the placebo).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 04, 2020
Details:
Study objectives A safety and tolerability assessment of the drug "Gam-COVID-Vac ", solution for intramuscular administration, using single dose of each component.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Avifavir
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Russian Direct Investment Fund (RDIF)
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 02, 2020
Details:
The joint venture established by RDIF and ChemRar Group provided an additional opportunity to increase production capacity threefold, up to 300,000 courses per month.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2020
Details:
The Ministry of Health of the Russian Federation has granted a temporary registration certificate to Covid-19 treatment, Avifavir, produced by the Russian Direct Investment Fund (RDIF) and ChemRar Group.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
